Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer

NCT07382713 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Fluzoparib

Sponsor

Jinhua Zhou

Collaborators

[object Object]